Climb Bio reports Q3 2026 results, dosing underway in IgAN Phase 2 trial
Climb Bio started dosing in its NAVIGATE-2 Phase 2 trial of CLYM116 and reported new budoprutug data, with cash runway now guided into the second half of 2028.
SEC filing
4 stories
Climb Bio started dosing in its NAVIGATE-2 Phase 2 trial of CLYM116 and reported new budoprutug data, with cash runway now guided into the second half of 2028.
SEC filing
Low-dose budoprutug showed B-cell depletion and immunologic remission at Week 12, with additional Phase 2 data expected in 2027.
SEC filing
The companies said updated data show sustained APRIL suppression and a roughly 70% drop in a key pathogenic marker, supporting quarterly dosing ahead of a 2027 Phase 3 trial.
SEC filing
The company said a single 320 mg dose drove near-complete APRIL suppression and 60-75% IgA and Gd-IgA1 reduction through 12 weeks, supporting a possible every-12-week dosing schedule.
SEC filing